Hikma Pharmaceuticals PLC (HKMPF)
OTCMKTS · Delayed Price · Currency is USD
26.38
0.00 (0.00%)
At close: Jul 30, 2025
Beacon Roofing Supply Revenue
In the year 2024, Hikma Pharmaceuticals had annual revenue of $3.13B with 8.77% growth. Hikma Pharmaceuticals had revenue of $1.56B in the half year ending December 31, 2024, with 19.48% growth.
Revenue
3.13B
Revenue Growth
+8.77%
P/S Ratio
1.81
Revenue / Employee
329.16K
Employees
9,500
Market Cap
5.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.13B | 252.00M | 8.77% |
| Dec 31, 2023 | 2.88B | 358.00M | 14.22% |
| Dec 31, 2022 | 2.52B | -36.00M | -1.41% |
| Dec 31, 2021 | 2.55B | 212.00M | 9.06% |
| Dec 31, 2020 | 2.34B | 134.00M | 6.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
Hikma Pharmaceuticals News
- 9 days ago - Hikma Pharmaceuticals: a quality compounder waiting for a catalyst - The Armchair Trader
- 4 weeks ago - Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US - PRNewsWire
- 4 weeks ago - Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D - Seeking Alpha
- 5 weeks ago - Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines - PRNewsWire
- 2 months ago - Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection - PRNewsWire
- 2 months ago - Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection - PRNewsWire
- 3 months ago - Hikma acquires Novugen's FDA-approved ANDA for trametinib - PRNewsWire
- 5 months ago - Hikma Pharmaceuticals PLC (HKMPF) Q4 2024 Earnings Call Pre-Recorded (Transcript) - Seeking Alpha